The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

A new five-year joint funding agreement between the United States and Lesotho promises to restore stability to a health ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

Measles is popping up in pockets across the country, and with holiday travel and colder weather setting in, it’s time to be ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

The agency that distributed nearly half of all clean syringes provided to drug users in West Virginia last year will end its ...